Elutia unaffected by global tariffs, maintains US focus

SILVER SPRING, Md. – Elutia Inc. (NASDAQ: ELUT), a developer of drug-eluting biomatrix products with annual revenue of $24.38 million and a gross margin of 43.93%, announced today that the current global tariff environment has not materially impacted its commercial or operational performance. According to InvestingPro data, the company’s shares have declined nearly 42% year-to-date, suggesting investors may have concerns beyond tariff impacts. The company, which sources, manufactures, and sells its products exclusively in the United States, credits its vertically integrated manufacturing and domestic commercial strategy for this stability.

Dr. Randy Mills, CEO of Elutia, stated, "Thanks to our vertically integrated manufacturing and U.S.-focused commercial strategy, we remain insulated from the uncertainties surrounding the current tariff landscape and continue to reliably produce and deliver our advanced medical products so patients can thrive without compromise." However, InvestingPro analysis reveals the company faces financial challenges, with short-term obligations exceeding liquid assets and a current ratio of 0.69.

Elutia’s main production facility located in Roswell, Georgia, is FDA-registered and has reportedly faced no delays, cost increases, or supplier issues as a result of tariffs. The company believes this positions it to continue serving the U.S. market effectively without impacts on its pricing or margins.

The company’s product line, including EluPro™, CanGaroo®, SimpliDerm®, and its Cardiovascular portfolio, is entirely produced and distributed within the U.S. This approach appears to shield Elutia from the tariff-related challenges that could affect companies with international supply chains or customer bases.

Elutia’s focus is on improving the compatibility between medical devices and patients who require them. With a mission to humanize medicine, the company aims to ensure that patients can benefit from implantable technologies without compromise.

Investors are reminded that this information is based on a press release statement. Forward-looking statements within the release indicate management’s belief that Elutia will not face future impacts from tariffs on its performance or the ability to secure necessary materials for its products. However, these statements are subject to risks and uncertainties that could cause actual results to differ materially from the anticipated outcomes. For deeper insights into Elutia’s financial health and future prospects, investors can access comprehensive analysis and 7 additional ProTips through InvestingPro’s detailed research reports, available for over 1,400 US stocks.

In other recent news, Elutia Inc. reported its fourth-quarter 2024 earnings, missing both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.26, below the expected -$0.24, and revenue of $5.47 million, falling short of the anticipated $6.3 million. Despite the earnings miss, Elutia announced a significant agreement with Advantus Health Partners to include its EluPro™ Antibiotic Eluting BioEnvelope in Advantus’s group purchasing organization portfolio. This collaboration is expected to expand EluPro’s market reach. Additionally, Elutia’s strategic partnership with Boston Scientific aims to drive further growth. Meanwhile, Aziyo Biologics reported a year-over-year revenue decline of approximately 7% to $5.5 million for the fourth quarter of 2024. Cantor Fitzgerald maintained its $8.00 price target for Aziyo Biologics, expressing optimism for the company’s prospects in 2025, particularly due to the successful pilot launch and anticipated sales of EluPro by Boston Scientific. The firm noted the potential for Aziyo Biologics to capture a significant portion of the market, currently dominated by Medtronic, whose product is considered less advanced.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.